A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.

被引：0
|
作者：
Kadowaki, Shigenori [1 ]
Masuishi, Toshiki [1 ]
Ura, Takashi [1 ]
Mitani, Seiichiro [1 ]
Narita, Yukiya [1 ]
Kato, Kyoko [1 ]
Honda, Kazunori [1 ]
Taniguchi, Hiroya [1 ]
Ando, Masashi [1 ]
Muro, Kei [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.856
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
856
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Ura, Takashi
    Sugiyama, Keiji
    Mitani, Seiichiro
    Narita, Yukiya
    Taniguchi, Hiroya
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (04) : 701 - 707
  • [2] A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study
    Shigenori Kadowaki
    Toshiki Masuishi
    Takashi Ura
    Keiji Sugiyama
    Seiichiro Mitani
    Yukiya Narita
    Hiroya Taniguchi
    Kei Muro
    International Journal of Clinical Oncology, 2021, 26 : 701 - 707
  • [3] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
    Saridaki, Z.
    Androulakis, N.
    Vardakis, N.
    Vamvakas, L.
    Kabouraki, E.
    Kalbakis, K.
    Hatzidaki, D.
    Voutsina, A.
    Mavroudis, D.
    Georgoulias, V.
    Souglakos, J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 1932 - 1937
  • [4] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
    Z Saridaki
    N Androulakis
    N Vardakis
    L Vamvakas
    E Kabouraki
    K Kalbakis
    D Hatzidaki
    A Voutsina
    D Mavroudis
    V Georgoulias
    J Souglakos
    British Journal of Cancer, 2012, 107 : 1932 - 1937
  • [5] Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial
    Souglakos, J
    Mavroudis, D
    Kakolyris, S
    Kourousis, C
    Vardakis, N
    Androulakis, N
    Agelaki, S
    Kalbakis, K
    Tsetis, D
    Athanasiadis, N
    Samonis, G
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2651 - 2657
  • [6] First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
    Masi, G
    Allegrini, G
    Cupini, S
    Marcucci, L
    Cerri, E
    Brunetti, I
    Fontana, E
    Ricci, S
    Andreuccetti, M
    Falcone, A
    ANNALS OF ONCOLOGY, 2004, 15 (12) : 1766 - 1772
  • [7] 5-Fluorouracil/Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) as First-Line Treatment of Advanced Gastric Cancer
    Grande, C.
    Martinez, M.
    Villanueva, M. J.
    Huidobro, G.
    Casal, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S469 - S469
  • [8] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [9] A phase II study of irinotecan, oxaliplatin, 5-fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer.
    Lee, J.
    Kang, W.
    Lee, S.
    Kwon, J.
    Kim, H.
    Lee, H.
    Lim, H.
    Park, J.
    Park, Y.
    Park, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197S
  • [10] Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
    Avallone, Antonio
    Giuliani, Francesco
    De Stefano, Alfonso
    Santabarbara, Giuseppe
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Rosati, Gerardo
    Cassata, Antonino
    Leo, Silvana
    Romano, Carmela
    Tamburini, Emiliano
    Silvestro, Lucrezia
    Lotesoriere, Claudio
    Nappi, Anna
    Santini, Daniele
    Petrillo, Antonella
    Colombo, Alfredo
    Febbraro, Antonio
    Leone, Alessandra
    Mannavola, Francesco
    Laterza, Maria Maddalena
    Izzo, Francesco
    Sobrero, Alberto
    Delrio, Paolo
    Giannarelli, Diana
    Budillon, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
12345